PRT 3789
Alternative Names: PRT-3789Latest Information Update: 12 Jul 2024
At a glance
- Originator Prelude Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action SMARCA2 protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 09 Jul 2024 Prelude Therapeutics and Merck collaborate to initiate a phase II trial in Solid tumours (Combination therapy)
- 09 Jul 2024 Prelude Therapeutics plans a phase II trial in Solid tumours (Combination therapy)
- 11 Oct 2023 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)